Feasibility of gadoteric acid for delayed gadolinium‐enhanced MRI of cartilage (dGEMRIC) at the wrist and knee and comparison with Gd‐DTPA

Abstract

2 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2017;46:1433-1440.

Cartilage quantification using contrast-enhanced MRI in the wrist of rheumatoid arthritis: cartilage loss is associated with bone marrow edema

“…Repeatability of our method was confirmed by almost perfect intraobserver reproducibility (ICC = 0.950 and 0.979 for SC and RS joints, respectively), which is comparable to that for dGEMRIC study of the wrist joints in healthy subjects utilizing gadoteric acid or Gd-DTPA at 3T magnet (ICC = 0.89). 18 The visual evaluation of joint space width using the SvdH method on radiographs revealed little joint space narrowing progression. This is compatible with the observation that there is no cartilage thinning on conventional MRI in the wrist joints of early RA patients by McQueen, et al 10 Miese, et al found significantly reduced dGEMRIC values without cartilage thickness alteration for the MCP joints of the index and middle fingers in patients with early RA, attributing glycosaminoglycan depletion of the MCP joint.…”

“…8 Recent studies have focused on evaluation of cartilage properties in wrist joints of healthy controls and osteomalacia patients on MR images acquired with delayed gadolinium enhanced MRI of cartilage (dGEMRIC). 17,18 The advantage of our in-house software is that it can detect cartilage area in carpal joints using conventional MR images; it takes less time to acquire images and data analysis is simpler compared to dedicated pulse sequences adopted in previous studies. 8,[17][18][19][20] Furthermore, our method does not require highly trained specialists who can evaluate cartilage visually because the software only requires simple ROI placements for the measurement of the adductor pollicis MSI and for the measurement of cartilage quantification.…”

“…17,18 The advantage of our in-house software is that it can detect cartilage area in carpal joints using conventional MR images; it takes less time to acquire images and data analysis is simpler compared to dedicated pulse sequences adopted in previous studies. 8,[17][18][19][20] Furthermore, our method does not require highly trained specialists who can evaluate cartilage visually because the software only requires simple ROI placements for the measurement of the adductor pollicis MSI and for the measurement of cartilage quantification. Repeatability of our method was confirmed by almost perfect intraobserver reproducibility (ICC = 0.950 and 0.979 for SC and RS joints, respectively), which is comparable to that for dGEMRIC study of the wrist joints in healthy subjects utilizing gadoteric acid or Gd-DTPA at 3T magnet (ICC = 0.89).…”

Feasibility of using half‐dose Gd‐BOPTA for delayed gadolinium‐enhanced MRI of cartilage (dGEMRIC) at the knee, compared with standard‐dose Gd‐DTPA

“…Qualitative image analysis was performed on a standard picture archiving and communication system (Centricity PACS, v. 4.0, GE Healthcare IT solutions, Barrington, IL) to select the morphological images, allowing coregistration and direct comparison of anatomic and functional datasets. T 1 parameter maps were independently analyzed on a separate multimodality workstation (Leonardo, Siemens Healthineers), using region‐of‐interest (ROI) analyses, by two musculoskeletal radiologists with 14 and 6 years of experience in the field, as previously recommended . For assessment of reliability, one reader evaluated the entire dataset and the second reader independently repeated the evaluation 4 weeks later to assess interobserver agreement.…”

“…Many factors have to be considered when choosing the appropriate contrast agent for MRI . With gadoteric acid (Gd‐DOTA), there is to date only one alternative GBCA for dGEMRIC, which has recently been validated using an equimolar dose in healthy cartilage at the wrist and knee and has also been used at the hip . Gadobenate dimeglumine (Gd‐BOPTA, MultiHance, Bracco Imaging, Milan, Italy) is an US Food and Drug Administration (FDA)‐approved, second‐generation GBCA that is widely used as an MRI contrast agent.…”